Discriminative stimulus effects of midazolam and abecarnil in rats treated chronically with diazepam or abecarnil

D. A. Lytle, M. W. Emmett-Oglesby, D. N. Stephens

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Abecarnil (ABC) is a beta-carboline that acts as an agonist at benzodiazepine (BZD) receptors. It possesses anxiolytic and anticonvulsant properties, but produces little sedation and is without muscle relaxant effects. To explain this unusual profile of activity, two hypotheses have been advanced: either 1) ABC acts as a partial agonist or 2) ABC acts as a full agonist, but only at a sub-population of BZD receptors. The present experiment used cross-tolerance profiles between BZDs and ABC to differentiate these hypotheses based upon predictions of receptor theory: tolerance produced to a full agonist should confer even greater cross-tolerance to a partial agonist. Rats were trained in a three-choice drug discrimination procedure to detect the benzodiazepine, midazolam (MDZ, 1.0 mg/kg) from pentylenetetrazole (PTZ, 20 mg/kg) from saline. Tested acutely, MDZ and ABC substituted for MDZ with similar potencies. Following chronic treatment with the BZD-agonist diazepam (DZP; 20 mg/kg per 8 h for 7 days), both the MDZ and ABC dose-effect curves were significantly shifted to the right, and both drugs showed a comparable three-fold decrease in potency. The chronic administration of ABC (4.0 mg/kg per 8 h for 7 days) produced a different spectrum of results. No significant shift occurred in the MDZ dose-effect curve, but there was a significant seven-fold shift to the right of the ABC dose-effect curve. Throughout all tests, PTZ-lever responding rarely occurred and did not account for more than 20% of lever selections for any individual test. These data support the hypothesis that ABC acts as a full agonist at a sub-population of BZD receptors, which mediate its substitution for MDZ.

Original languageEnglish
Pages (from-to)339-346
Number of pages8
JournalPsychopharmacology
Volume121
Issue number3
DOIs
StatePublished - 1 Oct 1995

Fingerprint

Midazolam
Diazepam
GABA-A Receptors
norharman
Benzodiazepines
abecarnil
Pentylenetetrazole
Anti-Anxiety Agents
Pharmaceutical Preparations
Anticonvulsants
Population
Muscles

Keywords

  • Abecarnil
  • Benzodiazepine
  • Cross-tolerance
  • Diazepam
  • Discriminative stimulus
  • Midazolam
  • Partial agonist
  • Tolerance

Cite this

@article{d43ec8a6fcd94e0297616288ba155ff0,
title = "Discriminative stimulus effects of midazolam and abecarnil in rats treated chronically with diazepam or abecarnil",
abstract = "Abecarnil (ABC) is a beta-carboline that acts as an agonist at benzodiazepine (BZD) receptors. It possesses anxiolytic and anticonvulsant properties, but produces little sedation and is without muscle relaxant effects. To explain this unusual profile of activity, two hypotheses have been advanced: either 1) ABC acts as a partial agonist or 2) ABC acts as a full agonist, but only at a sub-population of BZD receptors. The present experiment used cross-tolerance profiles between BZDs and ABC to differentiate these hypotheses based upon predictions of receptor theory: tolerance produced to a full agonist should confer even greater cross-tolerance to a partial agonist. Rats were trained in a three-choice drug discrimination procedure to detect the benzodiazepine, midazolam (MDZ, 1.0 mg/kg) from pentylenetetrazole (PTZ, 20 mg/kg) from saline. Tested acutely, MDZ and ABC substituted for MDZ with similar potencies. Following chronic treatment with the BZD-agonist diazepam (DZP; 20 mg/kg per 8 h for 7 days), both the MDZ and ABC dose-effect curves were significantly shifted to the right, and both drugs showed a comparable three-fold decrease in potency. The chronic administration of ABC (4.0 mg/kg per 8 h for 7 days) produced a different spectrum of results. No significant shift occurred in the MDZ dose-effect curve, but there was a significant seven-fold shift to the right of the ABC dose-effect curve. Throughout all tests, PTZ-lever responding rarely occurred and did not account for more than 20{\%} of lever selections for any individual test. These data support the hypothesis that ABC acts as a full agonist at a sub-population of BZD receptors, which mediate its substitution for MDZ.",
keywords = "Abecarnil, Benzodiazepine, Cross-tolerance, Diazepam, Discriminative stimulus, Midazolam, Partial agonist, Tolerance",
author = "Lytle, {D. A.} and Emmett-Oglesby, {M. W.} and Stephens, {D. N.}",
year = "1995",
month = "10",
day = "1",
doi = "10.1007/BF02246073",
language = "English",
volume = "121",
pages = "339--346",
journal = "Psychopharmacologia",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

Discriminative stimulus effects of midazolam and abecarnil in rats treated chronically with diazepam or abecarnil. / Lytle, D. A.; Emmett-Oglesby, M. W.; Stephens, D. N.

In: Psychopharmacology, Vol. 121, No. 3, 01.10.1995, p. 339-346.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Discriminative stimulus effects of midazolam and abecarnil in rats treated chronically with diazepam or abecarnil

AU - Lytle, D. A.

AU - Emmett-Oglesby, M. W.

AU - Stephens, D. N.

PY - 1995/10/1

Y1 - 1995/10/1

N2 - Abecarnil (ABC) is a beta-carboline that acts as an agonist at benzodiazepine (BZD) receptors. It possesses anxiolytic and anticonvulsant properties, but produces little sedation and is without muscle relaxant effects. To explain this unusual profile of activity, two hypotheses have been advanced: either 1) ABC acts as a partial agonist or 2) ABC acts as a full agonist, but only at a sub-population of BZD receptors. The present experiment used cross-tolerance profiles between BZDs and ABC to differentiate these hypotheses based upon predictions of receptor theory: tolerance produced to a full agonist should confer even greater cross-tolerance to a partial agonist. Rats were trained in a three-choice drug discrimination procedure to detect the benzodiazepine, midazolam (MDZ, 1.0 mg/kg) from pentylenetetrazole (PTZ, 20 mg/kg) from saline. Tested acutely, MDZ and ABC substituted for MDZ with similar potencies. Following chronic treatment with the BZD-agonist diazepam (DZP; 20 mg/kg per 8 h for 7 days), both the MDZ and ABC dose-effect curves were significantly shifted to the right, and both drugs showed a comparable three-fold decrease in potency. The chronic administration of ABC (4.0 mg/kg per 8 h for 7 days) produced a different spectrum of results. No significant shift occurred in the MDZ dose-effect curve, but there was a significant seven-fold shift to the right of the ABC dose-effect curve. Throughout all tests, PTZ-lever responding rarely occurred and did not account for more than 20% of lever selections for any individual test. These data support the hypothesis that ABC acts as a full agonist at a sub-population of BZD receptors, which mediate its substitution for MDZ.

AB - Abecarnil (ABC) is a beta-carboline that acts as an agonist at benzodiazepine (BZD) receptors. It possesses anxiolytic and anticonvulsant properties, but produces little sedation and is without muscle relaxant effects. To explain this unusual profile of activity, two hypotheses have been advanced: either 1) ABC acts as a partial agonist or 2) ABC acts as a full agonist, but only at a sub-population of BZD receptors. The present experiment used cross-tolerance profiles between BZDs and ABC to differentiate these hypotheses based upon predictions of receptor theory: tolerance produced to a full agonist should confer even greater cross-tolerance to a partial agonist. Rats were trained in a three-choice drug discrimination procedure to detect the benzodiazepine, midazolam (MDZ, 1.0 mg/kg) from pentylenetetrazole (PTZ, 20 mg/kg) from saline. Tested acutely, MDZ and ABC substituted for MDZ with similar potencies. Following chronic treatment with the BZD-agonist diazepam (DZP; 20 mg/kg per 8 h for 7 days), both the MDZ and ABC dose-effect curves were significantly shifted to the right, and both drugs showed a comparable three-fold decrease in potency. The chronic administration of ABC (4.0 mg/kg per 8 h for 7 days) produced a different spectrum of results. No significant shift occurred in the MDZ dose-effect curve, but there was a significant seven-fold shift to the right of the ABC dose-effect curve. Throughout all tests, PTZ-lever responding rarely occurred and did not account for more than 20% of lever selections for any individual test. These data support the hypothesis that ABC acts as a full agonist at a sub-population of BZD receptors, which mediate its substitution for MDZ.

KW - Abecarnil

KW - Benzodiazepine

KW - Cross-tolerance

KW - Diazepam

KW - Discriminative stimulus

KW - Midazolam

KW - Partial agonist

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=0028788398&partnerID=8YFLogxK

U2 - 10.1007/BF02246073

DO - 10.1007/BF02246073

M3 - Article

C2 - 8584616

AN - SCOPUS:0028788398

VL - 121

SP - 339

EP - 346

JO - Psychopharmacologia

JF - Psychopharmacologia

SN - 0033-3158

IS - 3

ER -